Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

RLFTF Stock: Why Relief Therapeutics and BRPA Stock Are Soaring Today

By Robert Lakin, InvestorPlace Contributor

After taking a hit in recent weeks, RLFTF stock investors got some good news on its respiratory failure treatment collaboration with BRPA target NeuroRx.

APOP Stock: Why Cellect Biotechnology Is Skyrocketing Today

By Robert Lakin, InvestorPlace Contributor

APOP stock holders are getting a 1:3 ratio of shares in the tie-up deal. The merger brings together Cellect's stem cell tech with Quoin's rare and orphan diseases focus.

SPFR Stock: 2 Reasons the Velo3D SPAC News Is Boosting Jaws Spitfire Today

By Robert Lakin, InvestorPlace Contributor

Jaws Spitfire Acquisition will bring Velo3D public just three months after raising $345 in the SPAC IPO. Ark Invest is just one of the money managers pouring into SPFR stock.

Blockchain Stocks: Why CAN, SOS and RIOT Stocks Are on the Move

By Robert Lakin, InvestorPlace Contributor

Blockchain stocks like RIOT stock are gaining this morning following bullish Bitcoin news from Elon Musk and the Federal Reserve.

CSCW Stock: Why Little-Known Color Star Is Gaining Big Today

By Robert Lakin, InvestorPlace Contributor

Non-fungible tokens continue to captivate investors, and the search for NFT stocks continues. CSCW stock actually has some relevance in the niche.

Load More